Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00943592 · ClinicalTrials.gov registry record · Phase 1
Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies
A Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 82
- Enrollment target
NCT00943592 is a Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 82 participants.
The verdict
NCT00943592, a Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 82 participants
- Enrollment target
Study Summary
This is a clinical research study designed to evaluate whether a conditioning regimen consisting of the combination of three drugs named melphalan, alemtuzumab and clofarabine supported by donor blood cells will result in rapid recovery and a high rate of long-lasting remissions in patients with leukemia, lymphoma and myeloma.
Interventions
- DRUG Melphalan
- DRUG Campath
- DRUG Clofarabine
- PROCEDURE Stem Cell Transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2006-03 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00943592
The ClinicalTrials.gov registry entry for NCT00943592 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Melphalan is the first listed.
NCT00943592 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00943592 about?
NCT00943592 is a clinical study titled "Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies". This is a clinical research study designed to evaluate whether a conditioning regimen consisting of the combination of three drugs named melphalan, alemtuzumab and clofarabine supported by donor blood cells will result in rapid recovery and a high rate of long-lasting remissions in patients with leu...
What is the current status of trial NCT00943592?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 82 participants. The study started on 2006-03. Estimated completion is 2013-11.
What interventions are being tested in trial NCT00943592?
The interventions under investigation include: Melphalan (DRUG), Campath (DRUG), Clofarabine (DRUG), Stem Cell Transplant (PROCEDURE).
Who is sponsoring clinical trial NCT00943592?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.